Skip to main content

Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring

The Original Article was published on 18 October 2022

Dear Editor,

Yang et al. published an important study that provided high-quality evidence for the therapeutic drug monitoring (TDM) range of polymyxin B in critically ill patients [1]. We want to add some comments.

It is well known that area under the curve/minimum inhibitory concentration (AUC/MIC) is the index that relates to polymyxin B’s efficacy [2]. Yang et al. found that the polymyxin B AUCss,24 h threshold of 50–100 mg·h/L was a suitable target for critically ill patients. Moreover, Yang et al. found that trough concentration had a good linear relationship with AUCss,24 h and trough concentration 1.2–2.8 mg/L could be an alternative for AUCss,24 h 50–100 mg·h/L in TDM. It is challenging to estimate AUC in routine clinical practice, while trough concentration-only monitoring is much easier and more feasible. However, the R2 of the correlation was only 0.793, and interindividual variance was not neglectable, indicating that the trough concentration could not reflect AUC well for individual patients.

Thus, we performed a Monte Carlo simulation based on a published population pharmacokinetic model, which was developed by Yang’s team and was used for AUC estimation in Yang’s study [3]. NONMEM (version 7.5.0, ICON, Ellicott City, MD, United States) coupled with PDxPop (version 5.3, ICON, Gaithersburg, MD, United States) were used for simulation. Renal clearance was set to 50, 100 and 150 mL/min, and the daily dose was 100, 150 and 200 mg, which was divided into 2 doses. A total of 9000 virtual patients were generated (1000 virtual patients for each clearance and daily dose combination), and the plasma concentration after multiple doses was simulated. AUCss,24 h of virtual patients were calculated using the pkr package (version 0.1.3) in R software (version 4.0.5) with a linear-up and linear-down method.

The relationship between the simulated trough concentrations and AUCss,24 h is shown in Fig. 1. A, which is similar to Yang et al.’s study. However, for patients with a trough concentration of 1.2–2.8 mg/L, the AUCss,24 h ranged from 37 to 216 mg·h/L, and only 73.6% were in the range of 50–100 mg·h/L (Fig. 1B). For patients with an AUCss,24 h of 50–100 mg·h/L, the trough concentration also varied, and only 61.9% of the patients had a trough concentration of 1.2–2.8 mg/L (Fig. 1C). Thus, trough concentration and AUCss,24 h of polymyxin B are inconsistent. Trough concentration may not be a good target for polymyxin B TDM from pharmacokinetic simulation results. Future studies are needed to provide a suitable strategy for polymyxin B TDM.

Fig. 1
figure 1

Relationship of trough concentration and area under the curve at steady status after multiple doses of intravenous polymyxin B. AUC: 24-h area under the curve at steady status; CT: trough concentration at steady status. A Linear relationship of trough concentration and AUC; B AUC distribution for patients with trough concentration 1.2–2.8 mg/L; C Trough concentration distribution for patients with AUC 50–100 mg·h/L

Yang et al.’s study found a relationship between AUCss,24 h and clinical response, rather than AUCss,24 h and mortality. This may be due to the inclusion of patients with various infection sites. The dose of intravenous polymyxin B was suboptimal for lung infection, which was the highest infection rate in the study (305/393) [2, 4]. Plasma concentration or AUCss,24 h of polymyxin B was also irrelevant to the clinical efficacy of urinary tract infection and cerebral infection, as intravenous polymyxin B was rarely excreted through the kidney or distributed to cerebrospinal fluid [4, 5].

There is an error in Fig. 4(a) of original study that should be addressed. The total number of patients with AUCss,24 h > 49.1 mg·h/L should be 202, not 393. However, the conclusion was not affected.

Availability of data and materials

Not applicable.


  1. Yang J, Liu S, Lu J, Sun T, Wang P, Zhang X. An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria. Crit Care BioMed Cent. 2022;26:320.

    Article  Google Scholar 

  2. Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 2018;73:462–8.

    Article  CAS  Google Scholar 

  3. Wang P, Zhang Q, Zhu Z, Feng M, Sun T, Yang J, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol. 2020;11:1–10.

    Article  CAS  Google Scholar 

  4. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins. Pharmacotherapy. 2019;39:10–39.

    Article  Google Scholar 

  5. Liu X, Chen Y, Yang H, Li J, Yu J, Yu Z, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects. J Infect. 2021;82:207–15.

    Article  CAS  Google Scholar 

Download references


We would like to thank Ms Jieqiong Liu from the 903 Hospital of the Joint Logistic Support Force of the PLA, Hangzhou, for her help in data processing.


Funding was supported by the National Natural Science Foundation of China (81903667) and the Zhejiang Provincial Natural Science Foundation (LYY21H310006).

Author information

Authors and Affiliations



ZY raised the problem and wrote the letter; YZ and HC performed the analysis and drew the figure. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Zhenwei Yu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests


Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, Y., Chen, H. & Yu, Z. Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring. Crit Care 27, 41 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: